The move towards personalized healthcare continues to gain momentum as consumers seek to manage their health proactively rather than relying solely on traditional medical systems. This shift is influenced by technological advancements and the desire for a more tailored approach to healthcare. In response, CoreVitals, a health tech startup based in London, is stepping into the spotlight, offering a new solution to track and interpret health data comprehensively.
In the past, personalized healthcare has often been synonymous with expensive devices or exclusive memberships, usually accessible only to affluent customers. A noticeable gap persisted between advanced diagnostics and their practical application in everyday health management. Various startups aimed to address these disparities, yet the market’s offerings remained fragmented until recently. CoreVitals emerges amid this landscape with a model that strives to democratize access to advanced diagnostics, attempting to bridge a long-standing gap in the healthcare sector.
Why is CoreVitals Challenging the Status Quo?
CoreVitals distinguishes itself by offering more than a typical standalone test. It combines over 100 blood biomarkers to provide thorough insights into cardiovascular, liver, kidney, hormone, nutritional, immune, and metabolic health. This broad approach contrasts with traditional models that usually emphasise isolated tests, which could overlook potential health issues. According to Millie O’Brien from CoreVitals, biases in test selection can lead to incomplete health assessments.
“We wanted to avoid that bias. So our panel was designed by GPs and covers everything from early cancer detection to hormonal health, nutrients, and more.”
How Does CoreVitals Aim to Integrate with the NHS?
For CoreVitals, aligning with the trusted infrastructure of the UK’s National Health Service remains a priority to ensure credibility. This integration intends to streamline the diagnostic process by minimizing hurdles traditionally associated with NHS services. Services like Randox Health labs, widely used by private GPs, reflect CoreVitals’ strategic partnerships. These collaborations enhance the credibility and accessibility of the service, positioning it as both an alternative and a complement to existing healthcare systems.
“Ordering tests through the NHS is already a nightmare. Most private GPs already use labs like Randox Health.”
CoreVitals expands its reach by not confining its services to just individuals. Its business model embraces partnerships with professionals across various fields such as nutritionists, functional medicine specialists, and fertility experts. The B2B2C approach intends to provide seamless integration of their diagnostic results into medical practice, ensuring that healthcare professionals have direct access to patient data without the bottleneck of traditional systems.
The increased innovation in healthtech is visible not only in CoreVitals’ endeavors but also in startups like Vivian Lab and Solence, focused on women’s health, or Koios Care, addressing Parkinson’s. These companies depict a broader trend of leveraging technology for preventative health. CoreVitals, however, insists that its comprehensive approach towards diagnostics, emphasising routine monitoring rather than episodic tests, provides deeper insights for sustained health management.
“Our tests are actionable, with regular tracking and personalisation. We’re also building a strong clinical team and advisory board to support the product with medical depth, not just visuals, and real support.”
User education and overcoming preconceived notions about diagnostics remain challenges for CoreVitals. Meeting these with condition-specific communication strategies, such as detailing the benefits for individuals with PCOS or addressing hormonal changes in middle age, the startup aims to demystify their product offering.
Even as the company caters to its initial users, manual evaluation of results by GPs ensures accuracy. Such steps are crucial as CoreVitals targets an eventual scaling to a wider audience. The brand’s dedication to integrating large public datasets to refine their insights is a testament to their commitment to evolving and expanding personalized healthcare.
